HUMANA ALERT: Bragar Eagel & Squire, P.C. is Investigating Humana Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Humana Inc. due to a class action lawsuit alleging breaches of fiduciary duties by the board of directors during a specified class period [1]. Group 1: Class Action Lawsuit Details - The class action lawsuit against Humana alleges that the company made false or misleading statements regarding its adjusted earnings-per-share, particularly downplaying the impact of increased medical costs from pent-up demand for healthcare services [3]. - The lawsuit cites that on June 13, 2023, UnitedHealth Group Inc. reported higher outpatient care activity, which led to an over 11% drop in Humana's stock price [4]. - Following this, on June 16, 2023, Humana reported higher than anticipated non-inpatient utilization trends, resulting in a decline in its stock price [5]. - On January 18, 2024, Humana disclosed an increase in its benefits expense ratio to approximately 91.4% for Q4 2023, causing nearly an 8% drop in stock price [6]. - The lawsuit further claims that on January 25, 2024, Humana announced a loss of $4.42 per share for Q4 2023, driven by higher inpatient utilization, leading to a nearly 12% decline in stock price [7].